Sanuwave Health (NASDAQ:SNWV) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Sanuwave Health (NASDAQ:SNWV) from a hold rating to a strong sell rating in a report published on Monday morning,Zacks.com reports.

SNWV has been the subject of several other reports. Wall Street Zen cut Sanuwave Health from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Roth Mkm reiterated a “buy” rating and issued a $47.00 price objective (down from $53.00) on shares of Sanuwave Health in a research report on Monday. Finally, Weiss Ratings raised Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Sanuwave Health Trading Down 2.5%

Shares of SNWV opened at $16.85 on Monday. The firm has a market cap of $144.74 million, a price-to-earnings ratio of -105.31 and a beta of 1.52. The company has a debt-to-equity ratio of 10.08, a quick ratio of 1.05 and a current ratio of 1.38. Sanuwave Health has a fifty-two week low of $16.27 and a fifty-two week high of $46.58. The firm has a 50 day moving average price of $23.41 and a 200-day moving average price of $28.98.

Sanuwave Health (NASDAQ:SNWV) last released its earnings results on Thursday, March 26th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.14). Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%. The business had revenue of $13.09 million for the quarter, compared to the consensus estimate of $13.23 million.

Institutional Investors Weigh In On Sanuwave Health

Several institutional investors and hedge funds have recently bought and sold shares of SNWV. Opaleye Management Inc. raised its holdings in shares of Sanuwave Health by 0.8% during the second quarter. Opaleye Management Inc. now owns 980,000 shares of the company’s stock valued at $32,203,000 after acquiring an additional 7,998 shares in the last quarter. Praetorian PR LLC increased its position in Sanuwave Health by 1,436.2% during the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock valued at $7,908,000 after purchasing an additional 247,750 shares during the period. Stifel Financial Corp purchased a new position in Sanuwave Health during the 4th quarter valued at $5,291,000. Geode Capital Management LLC raised its holdings in Sanuwave Health by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 167,256 shares of the company’s stock worth $4,992,000 after purchasing an additional 5,378 shares in the last quarter. Finally, CenterBook Partners LP lifted its position in shares of Sanuwave Health by 528.7% in the 3rd quarter. CenterBook Partners LP now owns 87,947 shares of the company’s stock worth $3,296,000 after purchasing an additional 73,959 shares during the period. Hedge funds and other institutional investors own 42.53% of the company’s stock.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.